Pre-emption On High: Supreme Court To Tackle Fraud Before Failure With Rezulin
Executive Summary
The U.S. Supreme Court is taking up a case that could limit when individuals can pursue state tort claims against drug manufacturers. On Sept. 25, the court granted Warner-Lambert's petition to hear a product liability case involving its diabetes drug Rezulin (troglitazone). At issue is whether federal law pre-empts a Michigan statute that allows someone to file a product liability claim if FDA has not found the manufacturer has concealed information from the agency
You may also be interested in...
FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008
As 2007 came to an end, lawyers, judges and others involved in pharmaceutical litigation had just one word on their minds: preemption
FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008
As 2007 came to an end, lawyers, judges and others involved in pharmaceutical litigation had just one word on their minds: preemption
FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases
A federal appellate court will take up the issue of whether FDA approved labeling preempts state litigation claiming companies failed to warn of a product's risks, following years of conflicting rulings from district courts